Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

December 15, 2022

Study Completion Date

January 11, 2023

Conditions

Advanced Solid TumorsPancreatic CancerCRC

Interventions

BIOLOGICAL

OMO-103

OMO-103 will be administered intravenously as 30 min infusion once weekly

Trial Locations (3)

Hospital Fundación Jiménez Díaz, Madrid

Hospital Universitario HM Sanchinarro, Madrid

University Hospital Vall d´Hebron, Barcelona